{"id":"tenofovir-disproxil-fumarate-emtricitabine","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Nausea"},{"rate":"10-15","effect":"Diarrhea"},{"rate":"10-15","effect":"Headache"},{"rate":"8-12","effect":"Fatigue"},{"rate":"1-3","effect":"Renal impairment (with TDF)"},{"rate":"2-5","effect":"Bone density loss (with TDF)"}]},"_chembl":{"chemblId":"CHEMBL1486","moleculeType":"Small molecule","molecularWeight":"635.52"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tenofovir disproxil fumarate (TDF) is a nucleotide reverse transcriptase inhibitor that is phosphorylated intracellularly to its active form, which competes with natural nucleotides and causes chain termination during HIV reverse transcription. Emtricitabine (FTC) is a nucleoside reverse transcriptase inhibitor with a similar mechanism. Together, this fixed-dose combination provides dual inhibition of reverse transcriptase, reducing viral replication and delaying the emergence of drug-resistant strains.","oneSentence":"Tenofovir disproxil fumarate and emtricitabine are nucleotide/nucleoside reverse transcriptase inhibitors that block HIV replication by inhibiting the enzyme responsible for converting viral RNA into DNA.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:11:32.663Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-naïve and treatment-experienced adults"},{"name":"HIV-1 pre-exposure prophylaxis (PrEP) in at-risk individuals"}]},"trialDetails":[{"nctId":"NCT04644029","phase":"PHASE3","title":"Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-02-24","conditions":"HIV-I, Human Immunodeficiency Virus Type 1, Prophylaxis","enrollment":730},{"nctId":"NCT04636437","phase":"PHASE4","title":"Doravirine for Obese Persons on Integrase Inhibitors and Tenofovir Alafenamide","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2021-07-27","conditions":"HIV Infections","enrollment":147},{"nctId":"NCT00729573","phase":"","title":"Bone Mineral Density Substudy - An Ancillary Study to MTN-003","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2009-11","conditions":"HIV Infections","enrollment":518},{"nctId":"NCT00705679","phase":"PHASE2","title":"Safety and Effectiveness of TFV 1% Gel, TDF Tablets, and FTC/TDF Tablets in Preventing HIV in Women","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2009-08","conditions":"HIV Infections","enrollment":5029},{"nctId":"NCT02474303","phase":"NA","title":"Demonstration Project of PrEP Among Female Sex Workers in Dakar, Senegal","status":"COMPLETED","sponsor":"Réseau Africain de Recherche sur le SIDA","startDate":"2015-07","conditions":"HIV/AIDS","enrollment":267}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"BLOOD CREATINE PHOSPHOKINASE INCREASED"},{"count":1,"reaction":"DIARRHOEA"},{"count":1,"reaction":"HEADACHE"},{"count":1,"reaction":"INTRACARDIAC MASS"},{"count":1,"reaction":"MATERNAL DRUGS AFFECTING FOETUS"},{"count":1,"reaction":"RENAL IMPAIRMENT"},{"count":1,"reaction":"STILLBIRTH"},{"count":1,"reaction":"VOMITING"}],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["TDF, FTC"],"phase":"marketed","status":"active","brandName":"tenofovir disproxil fumarate/emtricitabine","genericName":"tenofovir disproxil fumarate/emtricitabine","companyName":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","companyId":"advancing-clinical-therapeutics-globally-for-hiv-aids-and-other-infections","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tenofovir disproxil fumarate and emtricitabine are nucleotide/nucleoside reverse transcriptase inhibitors that block HIV replication by inhibiting the enzyme responsible for converting viral RNA into DNA. Used for HIV-1 infection in treatment-naïve and treatment-experienced adults, HIV-1 pre-exposure prophylaxis (PrEP) in at-risk individuals.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}